Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661563 · ClinicalTrials.gov registry record · NA
Advancing Scalable Alcohol Brief Interventions in the ED: A Trial of Conversational AI With Digital Reinforcements
A NA study, sponsored by Stanford University.
- Not yet
- Registry status
- NA
- Development phase
- 750
- Enrollment target
NCT07661563: Clinical Trial NA study, sponsored by Stanford University.
NCT07661563 is a NA study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 750 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07661563, a NA study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a novel digital strategy combining a generative AI counseling agent (MICA) and weekly SMS boosters works to reduce risky drinking among Emergency Department patients.
Primary Outcome
Participants report (1) the average number of days per week they consumed alcohol and (2) the typical number of standard drinks consumed on a drinking day. Estimated weekly alcohol consumption will be calculated as: Mean weekly drinks = (average drinking days per week) × (typical drinks per drinking day)
Interventions
- BEHAVIORAL MICA
- BEHAVIORAL TRAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-08 |
| Est. Completion | 2031-02 |
| Phase | NA |
What is known before NCT07661563 opens enrollment
NCT07661563 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which MICA is the first listed.
NCT07661563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07661563 about?
NCT07661563 is a clinical study titled "Advancing Scalable Alcohol Brief Interventions in the ED: A Trial of Conversational AI With Digital Reinforcements". The goal of this clinical trial is to learn if a novel digital strategy combining a generative AI counseling agent (MICA) and weekly SMS boosters works to reduce risky drinking among Emergency Department patients.
What is the current status of trial NCT07661563?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2026-08. Estimated completion is 2031-02.
What interventions are being tested in trial NCT07661563?
The interventions under investigation include: MICA (BEHAVIORAL), TRAC (BEHAVIORAL).
Who is sponsoring clinical trial NCT07661563?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07661563's enrollment target sits among peer trials
750 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia